<div id="readability-page-1"><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) released its earnings results on Wednesday. The company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.05, FiscalAI reports. MiMedx Group had a net margin of 10.38% and a return on equity of 27.19%. The company had revenue of $118.10 million for the quarter, compared to analyst estimates of $106.78 million.</p><p>Here are the key takeaways from MiMedx Group's conference call:</p><ul>   <li><span></span>MiMedx reported record 2025 results — full‑year net sales of <strong>$419M</strong> (+20%), Q4 net sales of <strong>$118M</strong> (+27%), adjusted EBITDA ~<strong>$106M</strong> and a net cash balance near <strong>$148M</strong>, strengthening profitability and liquidity.</li>   <li><span></span>The Medicare reimbursement reset (price cap ~$127/cm²) and WISeR prior‑auth implementation have caused near‑term disruption, lower ASPs and slower wound volumes; management guides 2026 revenue of <strong>$340–360M</strong> with adjusted EBITDA in the mid‑to‑high teens.</li>   <li><span></span>The surgical franchise is a clear growth driver — surgical sales grew ~25% in Q4 and 20% for the year, supported by increased commercial resources, new launches like <strong>AMNIOFIX Thyroid Shield</strong>, and recently licensed complementary surgical products.</li>   <li><span></span>Strong capital flexibility: the company holds substantial cash and the board authorized a <strong>$100M share repurchase program</strong> over two years while remaining open to disciplined M&amp;A to accelerate strategy.</li>   <li><span></span>Clinical evidence push: the <strong>EPIEFFECT randomized controlled trial</strong> is nearly fully enrolled with results and publications expected soon, and an RCT for <strong>CHORIOFIX</strong> is planned, reinforcing the company's evidence‑based positioning.</li> </ul><h2>MiMedx Group Stock Down 1.3%</h2><p>MDXG traded down $0.07 on Wednesday, reaching $5.28. The company's stock had a trading volume of 739,895 shares, compared to its average volume of 960,905. The company has a market capitalization of $781.98 million, a price-to-earnings ratio of 19.56 and a beta of 1.59. MiMedx Group has a fifty-two week low of $4.89 and a fifty-two week high of $8.46. The company has a quick ratio of 3.95, a current ratio of 4.41 and a debt-to-equity ratio of 0.07. The stock has a 50 day moving average of $5.82 and a two-hundred day moving average of $6.61. </p><h2>Institutional Inflows and Outflows</h2><p>Several large investors have recently modified their holdings of MDXG. Nantahala Capital Management LLC acquired a new stake in shares of  MiMedx Group during the third quarter worth about $10,237,000.  Marshall Wace LLP boosted its holdings in shares of  MiMedx Group by 864.9% in the fourth quarter. Marshall Wace LLP now owns 1,381,288 shares of the company's stock valued at $9,351,000 after acquiring an additional 1,238,132 shares during the period.  Disciplined Growth Investors Inc. MN grew its position in shares of  MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company's stock worth $9,656,000 after acquiring an additional 1,022,202 shares during the last quarter.  Millennium Management LLC increased its holdings in shares of  MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company's stock valued at $9,355,000 after acquiring an additional 596,016 shares during the period.  Finally, Ameriprise Financial Inc. increased its holdings in shares of  MiMedx Group by 5,332.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 559,058 shares of the company's stock valued at $3,416,000 after acquiring an additional 548,767 shares during the period. Institutional investors and hedge funds own  79.15% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>Several analysts have recently issued reports on the company. Citigroup started coverage on MiMedx Group in a research note on Monday. They issued a &#34;market outperform&#34; rating on the stock. Mizuho reduced their price target on MiMedx Group from $12.00 to $10.00 and set an &#34;outperform&#34; rating on the stock in a research report on Wednesday, December 17th. Citizens Jmp began coverage on MiMedx Group in a research note on Monday. They issued a &#34;market outperform&#34; rating and a $10.00 price objective for the company. UBS Group  set a $10.00 target price on shares of MiMedx Group in a research note on Monday. Finally, Wall Street Zen raised shares of MiMedx Group from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a report on Sunday, November 2nd. Five equities research analysts have rated the stock with a Buy rating and one  has assigned  a Hold rating to the company. According to MarketBeat, the stock  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $9.60.</p><p><b>View Our Latest Stock Report on MiMedx Group</b></p><h2>MiMedx Group Company Profile</h2> (Get Free Report)<p>MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company's core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx's product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.  </p><p>MiMedx's principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than MiMedx Group</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>This makes me furious</li><li>Buy this Gold Stock Before May 2026</li><li>What a Former CIA Agent Knows About the Coming Collapse</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYRw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2><p>Before you consider MiMedx Group, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p><p>While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MDXG

<p>MiMedx Group (NASDAQ:MDXG) reported quarterly earnings of $0.14 EPS, exceeding expectations of $0.09 by $0.05. The company generated $118.10 million in revenue, surpassing estimates of $106.78 million. With a net margin of 10.38% and a return on equity of 27.19%, MiMedx also announced a $100 million share repurchase program. Despite a 1.3% drop in stock price to $5.28, institutional investors have increased their stakes significantly. Analysts maintain a consensus rating of "Moderate Buy" with an average target price of $9.60.</p>

MiMedx Group (NASDAQ:MDXG) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS